Quantcast

Latest Monoclonal antibodies Stories

2014-06-24 08:29:37

CAMBRIDGE, England, June 24, 2014 /PRNewswire/ -- Sphere Fluidics Limited has developed unique technology for single cell analysis and characterization, and provides proprietary products and novel services for this rapidly-growing market. The Company has now just secured $2.3 million in a First Close of a new investment round. The latter will finally complete in early September 2014 with more potential funding already in the pipeline. "This is the first tranche of funding that...

2014-06-23 12:29:04

AUSTIN, Texas, June 23, 2014 /PRNewswire/ -- XBiotech announced today that Gary Gonzales has joined the Company as Vice President of Clinical Operations. Mr. Gonzales will lead XBiotech's clinical trial team and manage the Company's international clinical operations. Mr. Gonzales joins XBiotech from INC Research where he managed large, global pivotal phase III trials. Mr. Gonzales has B.S. & M.S. degrees in chemistry and biology and also holds a M.B.A. Mr. Gonzales comes to...

2014-06-19 09:35:10

The JAMA Network Journals In a study that included more than 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 years, although an increased risk of malignancy in the long term, or with increasing number of doses, cannot be excluded, according to a study in the June 18 issue of JAMA. Tumor necrosis factor α (TNF-α)...

2014-06-18 23:16:14

Bacterial recombinant protein expression is now available as a service at Maine Biotechnology Services. When MBS develops recombinant antigen for a hybridoma development, the end use application of the antibodies is considered during every phase of antigen production. Portland, Maine (PRWEB) June 18, 2014 Maine Biotechnology Services is announcing the addition of Bacterial Recombinant Protein Expression and Purification services to compliment our complete antibody service offering, adding...

2014-06-16 12:29:02

DEERFIELD, Ill., and OSAKA, Japan, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the United States (U.S.) commercial availability of a new biologic therapy, ENTYVIO((TM) )(vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD). "We understand how a great need still exists for additional treatment options...

2014-06-12 23:04:03

Ion Exchange Chromatography Reagents market can be segmented by Companies, Geographies, Applications, Products, Technologies and End Users. http://www.micromarketmonitor.com/market-report/ion-exchange-chromatography-reagents-reports-9812782514.html (PRWEB) June 12, 2014 The global ion exchange chromatography reagents market is projected to grow at a CAGR of about 11.0% from 2013 to 2018. Increased support from governments’ worldwide, increased usage of chromatographic techniques in the...

2014-06-11 23:13:29

New England Peptide and SISCAPA expand commercialization of mass spec biomarker assays. Gardner, MA (PRWEB) June 11, 2014 Today, New England Peptide, Inc. (NEP) and SISCAPA Assay Technologies, Inc. (SAT) announced a collaboration for the manufacture and sale of Stable Isotope Standard (SIS) peptides for use in SISCAPA® protein quantification assays. Under the terms of the agreement, NEP will manufacture peptide standards suitable for use with SAT’s SISCAPA assays. The peptides will...

2014-06-11 08:29:19

LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ -- RuiYi, Inc., a global therapeutic innovation leader, announced today the close of a $4 million debt financing from Silicon Valley Bank to advance a pipeline of novel monoclonal antibodies (mAb) targeting G protein coupled receptors (GPCRs). RuiYi plans to file an IND and initiate clinical trials in multiple countries in 2015 for the company's lead asset, RYI-008, a novel anti-IL-6 mAb for rheumatoid arthritis and cancer....

2014-06-11 08:29:17

New antibodies generated with RuiYi's iCAPS technology to explore GPCR structure and function LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ -- RuiYi, a global therapeutic innovation leader, and iHuman Institute at ShanghaiTech University announced today a new research collaboration applying RuiYi's iCAPS (Intermembranous Conformation Antigen Presenting System) technology to create novel monoclonal antibodies with specific binding to G protein coupled receptors (GPCRs) to...

2014-06-11 04:21:56

- Findings Show Positive Association Between Adherence and Anti-TNF Therapy Compared to Conventional Therapy PARIS, June 11, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related